Related Experiment Videos
Lung perfusion with clarithromycin ameliorates lung function after cardiopulmonary bypass
Xiangming Fan1, Yinglong Liu, Qiang Wang
1Department of Surgery, FuWai Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China. fanxiangming@126.com
The Annals of Thoracic Surgery
|February 21, 2006
Summary
Clarithromycin protects against lung injury following cardiopulmonary bypass by reducing inflammation and improving pulmonary function. This macrolide antibiotic demonstrates a significant protective effect in mitigating inflammatory responses.
Area of Science:
- Cardiovascular Surgery
- Pulmonary Medicine
- Pharmacology
Background:
- Macrolide antibiotics, like clarithromycin, can influence neutrophil function, a key factor in cardiopulmonary bypass-induced inflammation.
- Inflammatory lung injury is a known complication associated with cardiopulmonary bypass procedures.
Purpose of the Study:
- To investigate the protective effects of clarithromycin on inflammatory lung injury after cardiopulmonary bypass.
- To evaluate the impact of clarithromycin on neutrophil function and inflammatory markers in the context of cardiopulmonary bypass.
Main Methods:
- A study involving twelve adult sheep divided into control and experimental groups.
- The experimental group received lung perfusion with a dextran solution containing clarithromycin during cardiopulmonary bypass.
- Pulmonary function, inflammatory factors, and neutrophil apoptosis were assessed post-bypass.
Main Results:
- The clarithromycin group exhibited lower pulmonary vascular resistance and higher oxygen index compared to the control group.
- Significantly reduced levels of plasma myeloperoxidase, interleukin-8, and tumor necrosis factor were observed in the clarithromycin group.
- Histological analysis revealed reduced intra-alveolar hemorrhage and neutrophil accumulation in the clarithromycin-treated lungs, with a higher neutrophil apoptosis rate in the control group.
Conclusions:
- Lung perfusion with a hypothermic protective solution containing clarithromycin effectively inhibits inflammatory responses induced by cardiopulmonary bypass.
- Clarithromycin demonstrates a distinct ameliorative effect on lung function following cardiopulmonary bypass, highlighting its potential as a protective agent.